Literature DB >> 8101380

Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity.

J Brodkin1, A Malyala, J F Nash.   

Abstract

The effect of acute, reversible depletion of either serotonin [5-hydroxytryptamine (5-HT)] or dopamine (DA) on the long-term (7-day) decrease of brain 5-HT content produced after 3,4-methylenedioxymethamphetamine (MDMA) administration was investigated. The tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine (alpha-MPT) significantly attenuated the acute increase in DA efflux produced by MDMA in the striatum as measured by in vivo microdialysis. Treatment with alpha-MPT had no effect on MDMA-induced 5-HT release. alpha-MPT treatment blocked the long-term (7-day) depletion of striatal 5-HT content after MDMA administration. The tryptophan hydroxylase inhibitor p-chlorophenylalanine (PCPA) completely blocked the acute increase in the extracellular concentration of 5-HT produced by MDMA. Although PCPA significantly attenuated the increase in DA efflux produced by MDMA, the effect was small in magnitude. More importantly, treatment with PCPA had no effect on MDMA-induced decrease of 5-HT uptake sites in the frontal cortex. These data are suggestive that acute depletion of DA but not 5-HT protects against the long-term neurotoxic effects of MDMA on 5-HT axon terminals. In addition, these data are supportive of the hypothesis that DA plays a major role in the neurotoxic effects of MDMA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101380     DOI: 10.1016/0091-3057(93)90520-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

1.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

2.  MDMA induced dopamine release in vivo: role of endogenous serotonin.

Authors:  S Koch; M P Galloway
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

3.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

4.  The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.

Authors:  V Sanchez; J Camarero; B Esteban; M J Peter; A R Green; M I Colado
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

Authors:  R de la Torre; M Farré; J Ortuño; M Mas; R Brenneisen; P N Roset; J Segura; J Camí
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 6.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self-administration.

Authors:  Anne-Sophie Villégier; James D Belluzzi; Frances M Leslie
Journal:  Synapse       Date:  2010-11-09       Impact factor: 2.562

8.  Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine.

Authors:  D Zhou; M Schreinert; J Pilz; G Huether
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain.

Authors:  Thomas J R Beveridge; Annis O Mechan; Marie Sprakes; Qi Pei; Tyra S C Zetterstrom; A Richard Green; J Martin Elliott
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

Review 10.  Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons.

Authors:  Gary A Gudelsky; Bryan K Yamamoto
Journal:  Pharmacol Biochem Behav       Date:  2007-10-16       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.